RESUMEN
This study assessed the in vitro-in vivo correlation in cocrystal dissolution based on the coformer behavior. 4-Aminobenzoic acid (4ABA) was used as a coformer. Cocrystals of poorly water-soluble drugs with 4ABA, ketoconazole cocrystal (KTZ-4ABA), posaconazole cocrystal (PSZ-4ABA), and itraconazole cocrystal (ITZ-4ABA) were used. These three cocrystals generated supersaturated solutions in fasted state simulated intestinal fluid (FaSSIF) in a small-scale, 8 mL dissolution vessel. The time profile of the dissolved amount of 4ABA, an indicator of cocrystal dissolution, was significantly different among the three cocrystals. Under the conditions utilized, half of the KTZ-4ABA cocrystal solid rapidly dissolved within 5 min and the dissolved amount (% of applied amount) of KTZ and 4ABA was the same. Then, even though the residual solid cocrystal gradually dissolved, KTZ precipitated with time. The PSZ-4ABA cocrystal dissolved in a linear fashion with time but the dissolved concentration of PSZ reached a plateau in the supersaturated state and was maintained for at least 2 h. The dissolution rate of ITZ-4ABA was very slow compared to those of the other cocrystals, but a similar tendency was observed between cocrystal dissolution and the dissolved amount of ITZ. The rank order of the cocrystal dissolution rate based on the conformer concentration was KTZ-4ABA > PSZ-4ABA > ITZ-4ABA. Furthermore, cocrystallization of the three drugs with 4ABA significantly enhanced the oral drug absorption in rats. The rank order of the in vivo cocrystal dissolution rate by a deconvolution analysis with the plasma concentration-time profile of 4ABA was KTZ-4ABA > PSZ-4ABA > ITZ-4ABA, which corresponded well with the in vitro dissolution profiles of the cocrystals. These results indicate that analysis of cocrystal dissolution based on the coformer behavior may be useful to evaluate the in vitro and in vivo cocrystal dissolution.
Asunto(s)
Ácido 4-Aminobenzoico/química , Adyuvantes Farmacéuticos/química , Itraconazol/farmacocinética , Cetoconazol/farmacocinética , Triazoles/farmacocinética , Administración Oral , Animales , Química Farmacéutica , Cristalización , Composición de Medicamentos/métodos , Liberación de Fármacos , Absorción Gastrointestinal , Itraconazol/administración & dosificación , Itraconazol/química , Cetoconazol/administración & dosificación , Cetoconazol/química , Masculino , Ratas , Solubilidad , Triazoles/administración & dosificación , Triazoles/químicaRESUMEN
BACKGROUND: The antifungal drug itraconazole exerts in vitro activity against SARS-CoV-2 in Vero and human Caco-2 cells. Preclinical and clinical studies are required to investigate if itraconazole is effective for the treatment and/or prevention of COVID-19. METHODS: Due to the initial absence of preclinical models, the effect of itraconazole was explored in a clinical, proof-of-concept, open-label, single-center study, in which hospitalized COVID-19 patients were randomly assigned to standard of care with or without itraconazole. Primary outcome was the cumulative score of the clinical status until day 15 based on the 7-point ordinal scale of the World Health Organization. In parallel, itraconazole was evaluated in a newly established hamster model of acute SARS-CoV-2 infection and transmission, as soon as the model was validated. FINDINGS: In the hamster acute infection model, itraconazole did not reduce viral load in lungs, stools or ileum, despite adequate plasma and lung drug concentrations. In the transmission model, itraconazole failed to prevent viral transmission. The clinical trial was prematurely discontinued after evaluation of the preclinical studies and because an interim analysis showed no signal for a more favorable outcome with itraconazole: mean cumulative score of the clinical status 49 vs 47, ratio of geometric means 1.01 (95% CI 0.85 to 1.19) for itraconazole vs standard of care. INTERPRETATION: Despite in vitro activity, itraconazole was not effective in a preclinical COVID-19 hamster model. This prompted the premature termination of the proof-of-concept clinical study. FUNDING: KU Leuven, Research Foundation - Flanders (FWO), Horizon 2020, Bill and Melinda Gates Foundation.
Asunto(s)
Antivirales/farmacología , Tratamiento Farmacológico de COVID-19 , Itraconazol/farmacología , Animales , Antivirales/administración & dosificación , Antivirales/farmacocinética , Antivirales/uso terapéutico , COVID-19/etiología , COVID-19/transmisión , Chlorocebus aethiops , Modelos Animales de Enfermedad , Evaluación Preclínica de Medicamentos , Femenino , Humanos , Itraconazol/administración & dosificación , Itraconazol/farmacocinética , Itraconazol/uso terapéutico , Masculino , Mesocricetus , Persona de Mediana Edad , Neumonía Viral/tratamiento farmacológico , Neumonía Viral/patología , Neumonía Viral/virología , Prueba de Estudio Conceptual , SARS-CoV-2/efectos de los fármacos , Resultado del Tratamiento , Células VeroRESUMEN
We report a case of chromoblastomycosis due to the presence of large plaque and verrucous hyperplasia lesions on the left upper limb, with elbow abnormal activities, in a 56-year-old male. The diagnosis of chromoblastomycosis was based on gross and microscopic morphologies, histopathological examination and clinical manifestation. Molecular tools were applied to identifying the causative agent Fonsecaea nubica, which is rarely reported to be associated with chromoblastomycosis. The patient was initially treated orally with terbinafine (250 mg/day) and itraconazole (200 mg/day), subsequently patient received thermotherapy (45-50°C, 3 h/day) for 1 month. The patient was successfully cured. A literature review was performed to assess general features, treatment and outcome of chromoblastomycosis due to F. nubica. All the 5 reviewed patients were male, over 30 years old and their lesions occurred after traumatic inoculation.
Asunto(s)
Antifúngicos/administración & dosificación , Ascomicetos/aislamiento & purificación , Cromoblastomicosis/tratamiento farmacológico , Hipertermia Inducida , Itraconazol/administración & dosificación , Naftalenos/administración & dosificación , Ascomicetos/efectos de los fármacos , Cromoblastomicosis/microbiología , Cromoblastomicosis/patología , Histocitoquímica , Humanos , Masculino , Microscopía , Persona de Mediana Edad , Técnicas de Diagnóstico Molecular , Terbinafina , Resultado del Tratamiento , Extremidad Superior/patologíaRESUMEN
No data are available on the in vivo impact of infections with in vitro azole-resistant Aspergillus fumigatus in immunocompetent hosts. Here, the aim was to investigate fungal fitness and treatment response in immunocompetent mice infected with A. fumigatus (parental strain [ps]) and isogenic mutants carrying either the mutation M220K or G54W (cyp51A). The efficacy of itraconazole (ITC) and posaconazole (PSC) was investigated in mice, intravenously challenged either with a single or a combination of ps and mutants (6 × 105 conidia/mouse). Organ fungal burden and clinical parameters were measured. In coinfection models, no fitness advantage was observed for the ps strain when compared to the mutants (M220K and G54W) independent of the presence or absence of azole-treatment. For G54W, M220K, and the ps, no statistically significant difference in ITC and PSC treatment was observed in respect to fungal kidney burden. However, clinical parameters suggest that in particular the azole-resistant strain carrying the mutation G54W caused a more severe disease than the ps strain. Mice infected with G54W showed a significant decline in body weight and lymphocyte counts, while spleen/body weight ratio and granulocyte counts were increased. In immunocompetent mice, in vitro azole-resistance did not translate into therapeutic failure by either ITC or PSC; the immune system appears to play the key role in clearing the infection.
Asunto(s)
Antifúngicos/farmacología , Aspergilosis/microbiología , Aspergillus fumigatus/efectos de los fármacos , Azoles/farmacología , Farmacorresistencia Fúngica/efectos de los fármacos , Animales , Antifúngicos/administración & dosificación , Aspergilosis/tratamiento farmacológico , Aspergilosis/inmunología , Aspergilosis/patología , Aspergillus fumigatus/genética , Aspergillus fumigatus/patogenicidad , Azoles/administración & dosificación , Modelos Animales de Enfermedad , Farmacorresistencia Fúngica/genética , Femenino , Humanos , Itraconazol/administración & dosificación , Itraconazol/farmacología , Recuento de Linfocitos , Ratones , Ratones Endogámicos BALB C , Pruebas de Sensibilidad Microbiana , Mutación , Bazo/microbiología , Bazo/patología , Resultado del Tratamiento , Triazoles/administración & dosificación , Triazoles/farmacología , VirulenciaRESUMEN
BACKGROUND: Cutaneous leishmaniasis, caused by a parasitic infection, is considered one of the most serious skin diseases in many low- and middle-income countries. Old World cutaneous leishmaniasis (OWCL) is caused by species found in Africa, Asia, the Middle East, the Mediterranean, and India. The most commonly prescribed treatments are antimonials, but other drugs have been used with varying success. As OWCL tends to heal spontaneously, it is necessary to justify the use of systemic and topical treatments. This is an update of a Cochrane Review first published in 2008. OBJECTIVES: To assess the effects of therapeutic interventions for the localised form of Old World cutaneous leishmaniasis. SEARCH METHODS: We updated our searches of the following databases to November 2016: the Cochrane Skin Specialised Register, CENTRAL, MEDLINE, Embase, and LILACS. We also searched five trials registers and checked the reference lists of included studies for further references to relevant randomised controlled trials (RCTs). We wrote to national programme managers, general co-ordinators, directors, clinicians, WHO-EMRO regional officers of endemic countries, pharmaceutical companies, tropical medicine centres, and authors of relevant papers for further information about relevant unpublished and ongoing trials. We undertook a separate search for adverse effects of interventions for Old World cutaneous leishmaniasis in September 2015 using MEDLINE. SELECTION CRITERIA: Randomised controlled trials of either single or combination treatments in immunocompetent people with OWCL confirmed by smear, histology, culture, or polymerase chain reaction. The comparators were either no treatment, placebo/vehicle, and/or another active compound. DATA COLLECTION AND ANALYSIS: Two review authors independently assessed trials for inclusion and risk of bias and extracted data. We only synthesised data when we were able to identify at least two studies investigating similar treatments and reporting data amenable to pooling. We also recorded data about adverse effects from the corresponding search. MAIN RESULTS: We included 89 studies (of which 40 were new to this update) in 10,583 people with OWCL. The studies included were conducted mainly in the Far or Middle East at regional hospitals, local healthcare clinics, and skin disease research centres. Women accounted for 41.5% of the participants (range: 23% to 80%). The overall mean age of participants was 25 years (range 12 to 56). Most studies lasted between two to six months, with the longest lasting two years; average duration was four months. Most studies were at unclear or high risk for most bias domains. A lack of blinding and reporting bias were present in almost 40% of studies. Two trials were at low risk of bias for all domains. Trials reported the causative species poorly.Here we provide results for the two main comparisons identified: itraconazole (200 mg for six to eight weeks) versus placebo; and paromomycin ointment (15% plus 10% urea, twice daily for 14 days) versus vehicle.In the comparison of oral itraconazole versus placebo, at 2.5 months' follow up, 85/125 participants in the itraconazole group achieved complete cure compared to 54/119 in the placebo group (RR 3.70, 95% CI 0.35 to 38.99; 3 studies; 244 participants). In one study, microbiological or histopathological cure of skin lesions only occurred in the itraconazole group after a mean follow-up of 2.5 months (RR 17.00, 95% CI 0.47 to 612.21; 20 participants). However, although the analyses favour oral itraconazole for these outcomes, we cannot be confident in the results due to the very low certainty evidence. More side effects of mild abdominal pain and nausea (RR 2.36, 95% CI 0.74 to 7.47; 3 studies; 204 participants) and mild abnormal liver function (RR 3.08, 95% CI 0.53 to 17.98; 3 studies; 84 participants) occurred in the itraconazole group (as well as reports of headaches and dizziness), compared with the placebo group, but again we rated the certainty of evidence as very low so are unsure of the results.When comparing paromomycin with vehicle, there was no difference in the number of participants who achieved complete cure (RR of 1.00, 95% CI 0.86, 1.17; 383 participants, 2 studies) and microbiological or histopathological cure of skin lesions after a mean follow-up of 2.5 months (RR 1.03, CI 0.88 to 1.20; 383 participants, 2 studies), but the paromomycin group had more skin/local reactions (such as inflammation, vesiculation, pain, redness, or itch) (RR 1.42, 95% CI 0.67 to 3.01; 4 studies; 713 participants). For all of these outcomes, the certainty of evidence was very low, meaning we are unsure about these results.Trial authors did not report the percentage of lesions cured after the end of treatment or speed of healing for either of these key comparisons. AUTHORS' CONCLUSIONS: There was very low-certainty evidence to support the effectiveness of itraconazole and paromomycin ointment for OWCL in terms of cure (i.e. microbiological or histopathological cure and percentage of participants completely cured). Both of these interventions incited more adverse effects, which were mild in nature, than their comparisons, but we could draw no conclusions regarding safety due to the very low certainty of the evidence for this outcome.We downgraded the key outcomes in these two comparisons due to high risk of bias, inconsistency between the results, and imprecision. There is a need for large, well-designed international studies that evaluate long-term effects of current therapies and enable a reliable conclusion about treatments. Future trials should specify the species of leishmaniasis; trials on types caused by Leishmania infantum, L aethiopica, andL donovani are lacking. Research into the effects of treating women of childbearing age, children, people with comorbid conditions, and those who are immunocompromised would also be helpful.It was difficult to evaluate the overall efficacy of any of the numerous treatments due to the variable treatment regimens examined and because RCTs evaluated different Leishmania species and took place in different geographical areas. Some outcomes we looked for but did not find were degree of functional and aesthetic impairment, change in ability to detect Leishmania, quality of life, and emergence of resistance. There were only limited data on prevention of scarring.
Asunto(s)
Antiprotozoarios/uso terapéutico , Itraconazol/uso terapéutico , Leishmaniasis Cutánea/terapia , Paromomicina/uso terapéutico , Adulto , Animales , Antiinfecciosos/uso terapéutico , Antiprotozoarios/administración & dosificación , Terapias Complementarias/métodos , Crioterapia/métodos , Asia Oriental , Femenino , Calor/uso terapéutico , Humanos , Itraconazol/administración & dosificación , Terapia por Láser , Leishmania major , Leishmania tropica , Masculino , Persona de Mediana Edad , Medio Oriente , Bases Oleosas/administración & dosificación , Paromomicina/administración & dosificación , Fotoquimioterapia , Ensayos Clínicos Controlados Aleatorios como AsuntoRESUMEN
Objectives The goal of the present study was to compare the antifungal efficacy of an essential oil (EO) shampoo proven to be effective against Microsporum canis with miconazole/chlorhexidine for topical haircoat disinfection in cats treated concurrently with oral itraconazole. Methods Cats received treatment with oral itraconazole (Itrafungol) at a dose of 5 mg/kg/day pulse administration for 1 week, every 2 weeks for at least 6 weeks and were washed twice a week with a neutral shampoo with added EOs of Thymus serpyllum (2%), Origanum vulgare and Rosmarinus officinalis (5% each) for the period of systemic treatment. This protocol was compared with a conventional treatment (oral itraconazole + 2% miconazole/2% chlorhexidine shampoo). Results The treatment was well tolerated and adverse effects were not recorded. All cats were clinically negative at week 11. With respect to animals with extensive lesions, the speed of resolution was higher in cats with focal lesions. The animals showing diffuse lesions required more than a course of treatment to achieve a mycological cure. There was no significant difference between the number of weeks to obtain mycological cure for cats treated with EOs and animals treated conventionally. Conclusions and relevance The treatment appeared to be effective and well appreciated by the owners. The use of shampoo with the added EOs of T serpyllum, O vulgare and R officinalis would seem an interesting, natural alternative to conventional topical treatment.
Asunto(s)
Antifúngicos/uso terapéutico , Enfermedades de los Gatos/tratamiento farmacológico , Dermatomicosis/veterinaria , Preparaciones para el Cabello , Lamiaceae , Microsporum , Aceites de Plantas/uso terapéutico , Administración Oral , Animales , Antifúngicos/administración & dosificación , Enfermedades de los Gatos/parasitología , Gatos , Clorhexidina/administración & dosificación , Clorhexidina/uso terapéutico , Dermatomicosis/tratamiento farmacológico , Desinfección , Femenino , Itraconazol/administración & dosificación , Itraconazol/uso terapéutico , Masculino , Miconazol/administración & dosificación , Miconazol/uso terapéutico , Aceites de Plantas/administración & dosificación , Resultado del TratamientoRESUMEN
Paracoccidioides brasiliensis and P. lutzii belong to a group of thermodimorphic fungi and cause paracoccidioidomycosis (PCM), which is a human systemic mycosis endemic in South and Central America. Patients with this mycosis are commonly treated with amphotericin B (AmB) and azoles. The study of fungal virulence and the efficacy and toxicity of antifungal drugs has been successfully performed in a Galleria mellonella infection model. In this work, G. mellonella larvae were infected with two Paracoccidioides spp. and the efficacy and toxicity of AmB and itraconazole were evaluated in this model for the first time. AmB and itraconazole treatments were effective in increasing larval survival and reducing the fungal burden. The fungicidal and fungistatic effects of AmB and itraconazole, respectively, were observed in the model. Furthermore, these effects were independent of changes in haemocyte number. G. mellonella can serve as a rapid model for the screening of new antifungal compounds against Paracoccidioides and can contribute to a reduction in experimental animal numbers in the study of PCM.
Asunto(s)
Antifúngicos/administración & dosificación , Lepidópteros/microbiología , Paracoccidioides/efectos de los fármacos , Paracoccidioidomicosis/tratamiento farmacológico , Paracoccidioidomicosis/microbiología , Anfotericina B/administración & dosificación , Animales , Recuento de Colonia Microbiana , Modelos Animales de Enfermedad , Evaluación Preclínica de Medicamentos/métodos , Itraconazol/administración & dosificación , Larva/microbiología , Análisis de Supervivencia , Resultado del TratamientoRESUMEN
Ketoconazole has been widely used as a strong cytochrome P450 (CYP) 3A (CYP3A) inhibitor in drug-drug interaction (DDI) studies. However, the US Food and Drug Administration has recommended limiting the use of ketoconazole to cases in which no alternative therapies exist, and the European Medicines Agency has recommended the suspension of its marketing authorizations because of the potential for serious safety concerns. In this review, the Innovation and Quality in Pharmaceutical Development's Clinical Pharmacology Leadership Group (CPLG) provides a compelling rationale for the use of itraconazole as a replacement for ketoconazole in clinical DDI studies and provides recommendations on the best practices for the use of itraconazole in such studies. Various factors considered in the recommendations include the choice of itraconazole dosage form, administration in the fasted or fed state, the dose and duration of itraconazole administration, the timing of substrate and itraconazole coadministration, and measurement of itraconazole and metabolite plasma concentrations, among others. The CPLG's recommendations are based on careful review of available literature and internal industry experiences.
Asunto(s)
Antifúngicos/farmacocinética , Itraconazol/farmacocinética , Cetoconazol/farmacocinética , Antifúngicos/administración & dosificación , Ensayos Clínicos como Asunto , Interacciones Farmacológicas , Humanos , Itraconazol/administración & dosificación , Cetoconazol/administración & dosificaciónRESUMEN
In this study, we investigated the in vitro antifungal effects of itraconazole/voriconazole (ITR/VRC) alone and in combination with tetrandrine (TET) against 23 clinical isolates of A. fumigatus using a chequerboard microdilution method. The dynamic antifungal effects of TET with ITR/VRC against A. fumigatus were assessed in vivo using time-kill curves following systemic infection of mice with A. fumigatus. After treatment, efflux pump activity was determined by the efflux of rhodamine 6G (R6G). When ITR was combined with TET, ITR MICs were reduced from 0.125-32 to 0.0625-2 µg ml(-1), and TET MICs were reduced from 256-512 to 8-64 µg ml(-1). When VRC was combined with TET, VRC MICs were reduced from 0.125-2 to 0.03125-0.5 µg ml(-1), and TET MICs were reduced from 256-512 to 8-256 µg ml(-1). Time-kill curves revealed that A. fumigatus viability was reduced after treatment with ITR/VRC combined with TET versus ITR/VRC alone. ITR/VRC combined with TET significantly prolonged mouse survival and reduced kidney and brain tissue burdens versus ITR/VRC alone (P < 0.05). Moreover, TET inhibited R6G efflux of A. fumigatus. Thus, in vitro and in vivo, TET acted synergistically with ITR/VRC against A. fumigatus, and the synergistic mechanism was related to inhibition of the drug efflux pump.
Asunto(s)
Aspergilosis/tratamiento farmacológico , Aspergillus fumigatus/efectos de los fármacos , Bencilisoquinolinas/uso terapéutico , Itraconazol/uso terapéutico , Voriconazol/uso terapéutico , Animales , Antifúngicos/administración & dosificación , Antifúngicos/uso terapéutico , Aspergilosis/microbiología , Bencilisoquinolinas/administración & dosificación , Ciclofosfamida/toxicidad , Quimioterapia Combinada , Huésped Inmunocomprometido , Inmunosupresores/toxicidad , Itraconazol/administración & dosificación , Ratones , Pruebas de Sensibilidad Microbiana , Voriconazol/administración & dosificaciónRESUMEN
Current therapies used to treat dermatophytoses such as onychomycosis are effective but display room for improvement in efficacy, safety, and convenience of dosing. We report here that the investigational agent VT-1161 displays potent in vitro antifungal activity against dermatophytes, with MIC values in the range of ≤0.016 to 0.5 µg/ml. In pharmacokinetic studies supporting testing in a guinea pig model of dermatophytosis, VT-1161 plasma concentrations following single oral doses were dose proportional and persisted at or above the MIC values for at least 48 h, indicating potential in vivo efficacy with once-daily and possibly once-weekly dosing. Subsequently, in a guinea pig dermatophytosis model utilizing Trichophyton mentagrophytes and at oral doses of 5, 10, or 25 mg/kg of body weight once daily or 70 mg/kg once weekly, VT-1161 was statistically superior to untreated controls in fungal burden reduction (P < 0.001) and improvement in clinical scores (P < 0.001). The efficacy profile of VT-1161 was equivalent to those for doses and regimens of itraconazole and terbinafine except that VT-1161 was superior to itraconazole when each drug was dosed once weekly (P < 0.05). VT-1161 was distributed into skin and hair, with plasma and tissue concentrations in all treatment and regimen groups ranging from 0.8 to 40 µg/ml (or µg/g), at or above the MIC against the isolate used in the model (0.5 µg/ml). These data strongly support the clinical development of VT-1161 for the oral treatment of onychomycosis using either once-daily or once-weekly dosing regimens.
Asunto(s)
Antifúngicos/administración & dosificación , Antifúngicos/uso terapéutico , Piridinas/administración & dosificación , Piridinas/uso terapéutico , Tetrazoles/administración & dosificación , Tetrazoles/uso terapéutico , Tiña/tratamiento farmacológico , Animales , Antifúngicos/farmacocinética , Relación Dosis-Respuesta a Droga , Cobayas , Itraconazol/administración & dosificación , Itraconazol/uso terapéutico , Masculino , Pruebas de Sensibilidad Microbiana , Piridinas/farmacocinética , Piel/patología , Tetrazoles/farmacocinética , Tiña/microbiología , Tiña/patología , Distribución Tisular , Trichophyton/efectos de los fármacosRESUMEN
The purpose of this study was to improve in vitro dissolution and in vivo absorption of itraconazole (ITZ), a poorly water-soluble drug, by means of novel pectin-based nanoparticles prepared from nanoemulsion templates. Nanoemulsion templates were prepared by a high-pressure homogenization using pectin (i.e., 0.5-3.0%w/w low-methoxyl pectin (LMP), amidated low-methoxyl pectin (ALMP), or high-methoxyl pectin (HMP)) as an emulsifier and chloroform as an oil phase. HMP provided good oil-in-water emulsions with ITZ loaded in the oil phase. The chloroform in nanoemulsions was then removed to produce the suspensions of nanoparticles dispersed in water phase. After lyophilization, the dried core-shell nanoparticles with good properties in terms of redispersibility, dissolution, and stability were obtained. The alteration of ITZ crystallinity was clearly observed from powder X-ray diffractogram while no interaction between ITZ and pectin was found in the nanoparticles. The ITZ-loaded nanoparticles showed high percent drug dissolved, especially those prepared from HMP, and could maintain their good dissolution properties even after 6-month storage. The in vivo absorption study in fasted rats demonstrated that pectin-based nanoparticles prepared from nanoemulsion templates could improve absorption of ITZ, that is, 1.3-fold higher than the ITZ commercial product (p<0.05). Pectin type highly influenced the dissolution properties and also in vivo plasma profile. These findings suggested that HMP-based nanoparticles seem to be a promising formulation due to their high AUC(0-24h) and C(max).
Asunto(s)
Nanopartículas/química , Pectinas/química , Agua/química , Absorción , Animales , Área Bajo la Curva , Química Farmacéutica , Estabilidad de Medicamentos , Emulsiones/administración & dosificación , Emulsiones/química , Itraconazol/administración & dosificación , Itraconazol/química , Itraconazol/farmacocinética , Masculino , Nanopartículas/administración & dosificación , Aceites/química , Tamaño de la Partícula , Pectinas/administración & dosificación , Pectinas/farmacocinética , Ratas , Ratas Wistar , Solubilidad , Suspensiones/administración & dosificación , Suspensiones/químicaRESUMEN
This is the first report of a detailed relationship between triazole treatment history and triazole MICs for 154 Aspergillus fumigatus clinical isolates. The duration of itraconazole dosage increased as the itraconazole MIC increased, and a positive correlation was observed (r = 0.5700, P < 0.0001). The number of itraconazole-naïve isolates dramatically decreased as the itraconazole MIC increased, particularly for MICs exceeding 2 µg/ml (0.5 µg/ml versus 2 µg/ml, P = 0.03). We also examined the relationship between cumulative itraconazole usage and the MICs of other azoles. A positive correlation existed between itraconazole dosage period and posaconazole MIC (r = 0.5237, P < 0.0001). The number of itraconazole-naïve isolates also decreased as the posaconazole MIC increased, particularly for MICs exceeding 0.5 µg/ml (0.25 µg/ml versus 0.5 µg/ml, P = 0.004). Conversely, the correlation coefficient obtained from the scattergram of itraconazole usage and voriconazole MICs was small (r = -0.2627, P = 0.001). Susceptibility to three triazole agents did not change as the duration of voriconazole exposure changed. In addition, we carried out detailed analysis, including microsatellite genotyping, for isolates obtained from patients infected with azole-resistant A. fumigatus. We confirmed the presence of acquired resistance to itraconazole and posaconazole due to a G54 substitution in the cyp51A gene for a patient with chronic pulmonary aspergillosis after oral itraconazole therapy. We should consider the possible appearance of azole-resistant A. fumigatus if itraconazole is used for extended periods.
Asunto(s)
Aspergillus fumigatus/efectos de los fármacos , Aspergillus fumigatus/genética , Sistema Enzimático del Citocromo P-450/genética , Farmacorresistencia Fúngica/efectos de los fármacos , Proteínas Fúngicas/genética , Aspergilosis Pulmonar/tratamiento farmacológico , Anciano , Anciano de 80 o más Años , Antifúngicos/administración & dosificación , Antifúngicos/efectos adversos , Aspergillus fumigatus/enzimología , Aspergillus fumigatus/aislamiento & purificación , Sistema Enzimático del Citocromo P-450/metabolismo , Farmacorresistencia Fúngica/genética , Femenino , Proteínas Fúngicas/metabolismo , Humanos , Itraconazol/administración & dosificación , Itraconazol/efectos adversos , Masculino , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Mutación , Aspergilosis Pulmonar/microbiología , Factores de Tiempo , Triazoles/administración & dosificación , Triazoles/efectos adversosRESUMEN
Drug-loading transfersomes were prepared with itraconazole, a lipophilic drug, as a model drug to investigate the key factor affecting transfersomes quality and to evaluate their qualities. Drug-loading transfersomes were prepared using film dispersion method. The quality of transfersomes was evaluated by HPLC, transmission electron microscope, particle size analyzer and in vitro release. Itraconazole transfersomes was transparent solution in ivory white color with a mean entrapment efficiency of about 80%. The shape of hollow vesicles was spheroidal with the diameter of approximately 100 nm, and the zeta potential of 45 mV, which had a good transdermal effect. It can be concluded via single-factor investigation that the quality of transfersomes is significantly affected by solvent, salt ion concentration and homogenization pressure and so on. The preparation method obtained through screening and optimizing formulation and technology is feasible and the quality can be controlled.
Asunto(s)
Ácido Desoxicólico/química , Itraconazol/química , Lecitinas/química , Tensoactivos/química , Administración Cutánea , Animales , Ácido Desoxicólico/administración & dosificación , Itraconazol/administración & dosificación , Lecitinas/administración & dosificación , Liposomas , Ratas , Ratas Sprague-Dawley , Piel/anatomía & histología , Piel/efectos de los fármacos , Tensoactivos/administración & dosificaciónRESUMEN
CASE DESCRIPTION: A 1.5-year-old mixed-breed dog was examined because of a 1-month history of anorexia, vomiting, diarrhea, and weight loss. CLINICAL FINDINGS: The dog was very thin on physical examination (body condition score, 3/9). Results of all diagnostic tests were within reference limits except intestinal thickening and lymphadenopathy were identified on abdominal ultrasound examination. During exploratory laparotomy, thickening at the ileocecal-colic junction and within the transverse colon and mesenteric lymphadenopathy were identified, and the ileocecal-colic junction was resected. Histopathologic evaluation of the ileocecal-colic junction and full-thickness biopsy specimens from other sites as well as results of a serum ELISA were diagnostic for gastrointestinal Pythium insidiosum infection. TREATMENT AND OUTCOME: Pythiosis was initially treated medically with administration of itraconazole and terbinafine by mouth, but the colonic lesion was progressive with this regimen. Two months after diagnosis, a subtotal colectomy was performed; marginal excision (0.6 cm) was obtained at the aboral margin. The dog was treated with 3 doses of a pythiosis vaccine beginning approximately 2 weeks after surgery and was continued on itraconazole and terbinafine for 5 months. Parenteral and enteral nutrition as well as considerable general supportive care were required postoperatively. Six months after treatment, the dog had a normal serum ELISA titer. Two years after treatment, the dog had returned to preoperative weight and was clinically normal. CLINICAL RELEVANCE: This patient had an unusually positive therapeutic response to chronic, extensive, marginally excised gastrointestinal pythiosis.
Asunto(s)
Enfermedades de los Perros/microbiología , Enfermedades Intestinales/veterinaria , Pitiosis/veterinaria , Vacunas/inmunología , Animales , Antiinfecciosos/administración & dosificación , Antiinfecciosos/uso terapéutico , Enfermedades de los Perros/patología , Enfermedades de los Perros/terapia , Perros , Enrofloxacina , Fluoroquinolonas/uso terapéutico , Enfermedades Intestinales/microbiología , Enfermedades Intestinales/terapia , Itraconazol/administración & dosificación , Itraconazol/uso terapéutico , Masculino , Naftalenos/administración & dosificación , Naftalenos/uso terapéutico , Pitiosis/terapia , Pythium/inmunología , TerbinafinaAsunto(s)
Dermatomicosis/diagnóstico , Dermatomicosis/patología , Neoplasias de Células Escamosas/diagnóstico , Neoplasias de Células Escamosas/patología , Neoplasias Cutáneas/diagnóstico , Neoplasias Cutáneas/patología , Esporotricosis/diagnóstico , Esporotricosis/patología , Anciano de 80 o más Años , Antifúngicos/administración & dosificación , Dermatomicosis/microbiología , Dermatomicosis/terapia , Diagnóstico Diferencial , Humanos , Hipertermia Inducida , Itraconazol/administración & dosificación , Masculino , Neoplasias de Células Escamosas/terapia , Yoduro de Potasio/administración & dosificación , Neoplasias Cutáneas/terapia , Sporothrix/aislamiento & purificación , Esporotricosis/microbiología , Esporotricosis/terapia , Resultado del TratamientoRESUMEN
Itraconazole is used for the prevention and treatment of infections caused by Aspergillus fumigatus. An understanding of the pharmacodynamics of itraconazole against wild-type and triazole-resistant strains provides a basis for innovative therapeutic strategies for treatment of infections. An in vitro model of the human alveolus was used to define the pharmacodynamics of itraconazole. Galactomannan was used as a biomarker. The effect of systemic and airway administration of itraconazole was assessed, as was a combination of itraconazole administered to the airway and systemically administered 5FC. Systemically administered itraconazole against the wild type induced a concentration-dependent decline in galactomannan in the alveolar and endothelial compartments. No exposure-response relationships were apparent for the L98H, M220T, or G138C mutant. The administration of itraconazole to the airway resulted in comparable exposure-response relationships to those observed with systemic therapy. This was achieved without detectable concentrations of drug within the endothelial compartment. The airway administration of itraconazole resulted in a definite but submaximal effect in the endothelial compartment against the L98H mutant. The administration of 5FC resulted in a concentration-dependent decline in galactomannan in both the alveolar and endothelial compartments. The combination of airway administration of itraconazole and systemically administered 5FC was additive. Systemic administration of itraconazole is ineffective against Cyp51 mutants. The airway administration of itraconazole is effective for the treatment of wild-type strains and appears to have some activity against the L98H mutants. Combination with other agents, such as 5FC, may enable the attainment of near-maximal antifungal activity.
Asunto(s)
Antifúngicos/farmacología , Aspergilosis/tratamiento farmacológico , Aspergillus fumigatus/efectos de los fármacos , Itraconazol/farmacología , Enfermedades Pulmonares Fúngicas/tratamiento farmacológico , Alveolos Pulmonares/microbiología , Antifúngicos/administración & dosificación , Antifúngicos/farmacocinética , Aspergilosis/microbiología , Aspergilosis/prevención & control , Células Cultivadas , Vías de Administración de Medicamentos , Farmacorresistencia Fúngica , Flucitosina/administración & dosificación , Flucitosina/farmacología , Galactosa/análogos & derivados , Humanos , Itraconazol/administración & dosificación , Itraconazol/farmacocinética , Enfermedades Pulmonares Fúngicas/microbiología , Mananos/análisis , Pruebas de Sensibilidad Microbiana , Triazoles/farmacologíaRESUMEN
The aim of this study was to evaluate the ability of the Penn-Century Dry Powder Insufflator for mice (DP-4M) to reproducibly, uniformly, and deeply deliver dry powders for inhalation in the mouse lung. Itraconazole-based dry powder formulations produced by spray-drying were different in terms of composition (different ratios of drug and mannitol, with or without phospholipids), but relatively similar in terms of particle size and mass median aerodynamic diameter. The ability of the dry powder insufflator to disaggregate each formulation was the same, indicated by the absence of a statistically significant difference between the particle size distribution parameters, as measured by laser scattering. The emitted fraction varied in vivo compared to the in vitro condition. Fluorescent particle distribution in the lungs was uniform and reached the alveolar spaces, as visualized by fluorescent microscopy. In terms of drug recovery in lung tissue, a minimum administered powder mass (in this case â¼1 mg) was necessary to recover at least 30% of the emitted dose in the lung and to obtain reproducible pulmonary concentrations. To reduce the dose administered in the lung, it was preferable to dilute the active ingredient within the carrier instead of reducing the dry powder mass inserted in the sampling chamber. Dry powder insufflators are devices usable in dose-dependent preclinical trials but have critical parameters to efficiently deliver reproducible doses depending on the type of formulation.
Asunto(s)
Sistemas de Liberación de Medicamentos , Inhaladores de Polvo Seco , Itraconazol/administración & dosificación , Pulmón/metabolismo , Animales , Relación Dosis-Respuesta a Droga , Evaluación Preclínica de Medicamentos/métodos , Excipientes/química , Itraconazol/farmacocinética , Rayos Láser , Masculino , Manitol/química , Ratones , Ratones Endogámicos ICR , Microscopía Fluorescente , Tamaño de la Partícula , Fosfolípidos/química , Reproducibilidad de los Resultados , Dispersión de Radiación , Distribución TisularAsunto(s)
Antifúngicos/administración & dosificación , Cladosporium , Hipertermia Inducida , Itraconazol/administración & dosificación , Feohifomicosis/terapia , Administración Oral , Antifúngicos/uso terapéutico , Terapia Combinada , Femenino , Humanos , Hifa , Itraconazol/uso terapéutico , Persona de Mediana Edad , Técnicas de Tipificación Micológica , Feohifomicosis/microbiología , Feohifomicosis/patologíaRESUMEN
Nine consecutive isogenic Aspergillus fumigatus isolates cultured from a patient with aspergilloma were investigated for azole resistance. The first cultured isolate showed a wild-type phenotype, but four azole-resistant phenotypes were observed in the subsequent eight isolates. Four mutations were found in the cyp51A gene of these isolates, leading to the substitutions A9T, G54E, P216L, and F219I. Only G54 substitutions were previously proved to be associated with azole resistance. Using a Cyp51A homology model and recombination experiments in which the mutations were introduced into a susceptible isolate, we show that the substitutions at codons P216 and F219 were both associated with resistance to itraconazole and posaconazole. A9T was also present in the wild-type isolate and thus considered a Cyp51A polymorphism. Isolates harboring F219I evolved further into a pan-azole-resistant phenotype, indicating an additional acquisition of a non-Cyp51A-mediated resistance mechanism. Review of the literature showed that in patients who develop azole resistance during therapy, multiple resistance mechanisms commonly emerge. Furthermore, the median time between the last cultured wild-type isolate and the first azole-resistant isolate was 4 months (range, 3 weeks to 23 months), indicating a rapid induction of resistance.
Asunto(s)
Antifúngicos/administración & dosificación , Aspergilosis/tratamiento farmacológico , Aspergillus fumigatus/efectos de los fármacos , Sistema Enzimático del Citocromo P-450/genética , Farmacorresistencia Fúngica/efectos de los fármacos , Proteínas Fúngicas/genética , Itraconazol/administración & dosificación , Triazoles/administración & dosificación , Secuencia de Aminoácidos , Sustitución de Aminoácidos , Aspergilosis/microbiología , Aspergillus fumigatus/enzimología , Aspergillus fumigatus/genética , Sistema Enzimático del Citocromo P-450/metabolismo , Farmacorresistencia Fúngica/genética , Femenino , Proteínas Fúngicas/metabolismo , Genotipo , Humanos , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Modelos Moleculares , Datos de Secuencia Molecular , Mutagénesis Sitio-Dirigida , Tasa de Mutación , Fenotipo , Polimorfismo de Nucleótido Simple , Esputo/microbiología , Factores de TiempoRESUMEN
Liposomes are potential carriers for targeting and controlled drug delivery by the intravenous route. Carboxymethyl chitosan (CMC) is a ramification of chitosan with intrinsic water-solubility. The aim of this study is to prepare itraconazole-loaded liposomes coated by carboxymethyl chitosan (CMC-ITZ-Lips), to evaluate its physico-chemical characteristics and the tissue targeting after being injected intravenously (i.v.). This study uses a film dispersion method to prepare itraconazole-loaded liposomes (ITZ-Lips) prior to coating them with CMC. The concentrations of ITZ in selected organs were determined using reversed-phase high-performance liquid chromatography (HPLC) following i.v. administration of ITZ-Sol, ITZ-Lips, and CMC-ITZ-Lips. CMC-ITZ-Lips had an average diameter of 349.3 ± 18 nm with a zeta potential of -35.71 ± 0.62 mV and the in vitro antifungal activity was not inhibited by the entrapment. The CMC-ITZ-Lips exhibited a longer elimination half life (t(1/2ß)) in vivo compared with ITZ-Sol and ITZ-Lips after i.v. injection to mice. The biodistribution in mice was also changed after ITZ was encapsulated in CMC coated liposomes. CMC-ITZ-Lips performed significant lung targeting efficiency with AUC, Te and Re of lung all showed obvious elevation. In this study itraconazole was successfully encapsulated into carboxymethyl chitosan-modified liposomes for application of injection.